Trials / Suspended
SuspendedNCT07025512
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to examine the clinical and biological effects of 177Lu-PSMA-617 in mCRPC patients with cytopenia\[s\].
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 177Lu-PSMA-617 | Given by IV |
Timeline
- Start date
- 2025-08-03
- Primary completion
- 2027-06-30
- Completion
- 2029-06-30
- First posted
- 2025-06-17
- Last updated
- 2026-04-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07025512. Inclusion in this directory is not an endorsement.